Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer

Responses to immunotherapy are uncommon in estrogen receptor (ER)-positive breast cancer and to date, lack predictive markers. This randomized phase II study defines safety and response rate of epigenetic priming in ER-positive breast cancer patients treated with checkpoint inhibitors as primary end...

Descripción completa

Detalles Bibliográficos
Autores principales: Terranova-Barberio, Manuela, Pawlowska, Nela, Dhawan, Mallika, Moasser, Mark, Chien, Amy J., Melisko, Michelle E., Rugo, Hope, Rahimi, Roshun, Deal, Travis, Daud, Adil, Rosenblum, Michael D., Thomas, Scott, Munster, Pamela N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367885/
https://www.ncbi.nlm.nih.gov/pubmed/32681091
http://dx.doi.org/10.1038/s41467-020-17414-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367885/
https://www.ncbi.nlm.nih.gov/pubmed/32681091
http://dx.doi.org/10.1038/s41467-020-17414-y

Ejemplares similares